Half-year report · Q2
4572.TEDINET S100WEUS
Period2025-01-01 → 2025-06-30
Filed2025-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥251m | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥636m | 2024-01-01 → 2024-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥316m | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Operating income | −¥1.1bn | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Operating income | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Ordinary income | −¥1.1bn | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥2.1bn | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.1bn | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.2bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Net income | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Total assets | ¥1.6bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥2.8bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥3.7bn | at 2024-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥244m | at 2025-06-30 | Cons. | Liabilities |
| Total liabilities | ¥297m | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.4bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥2.5bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2024-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.1bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.1bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2023-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥995m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥222m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥16m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥14m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥567m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥279m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-55.29 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-121.64 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-63.25 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 85.1% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.3% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.2% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 8
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥1.0bn |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥251m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥251m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥51m |
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥1.1bn |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥316m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥316m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥24m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 418
| Item | Context | Value | Unit |
|---|---|---|---|
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -1665000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -887000 | JPY |
| Income taxes paid refund ope cf | Prior1YTDDuration | -8311000 | JPY |
| Income taxes paid refund ope cf | CurrentYTDDuration | -2341000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | -222059000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | -994641000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -7108000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -140000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | － | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -15743000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -7108000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -15884000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -59994000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -9996000 | JPY |
| Proceeds from stock issuance to a third party fin cf | Prior1YTDDuration | 342699000 | JPY |
| Proceeds from stock issuance to a third party fin cf | CurrentYTDDuration | － | JPY |
| Other net fin cf | Prior1YTDDuration | -3636000 | JPY |
| Other net fin cf | CurrentYTDDuration | -4010000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 279068000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -14006000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 87029000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | -23384000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 136929000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -1047915000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 2889101000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2108484000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 3026030000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 1060569000 | JPY |
| Allowance for doubtful accounts accounts receivable trade | Prior1YearInstant | － | JPY |
| Allowance for doubtful accounts accounts receivable trade | CurrentQuarterInstant | -571000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 992443000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 903056000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 315642000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 315642000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 315642000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Net sales | Prior1YTDDuration | 315642000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | -24361000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | -1070639000 | JPY |
| Operating income | Prior1YTDDuration | -1095000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | 251097000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 251097000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoverySupportBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00987-000DrugDiscoveryBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |